Uscom (ASX:UCM) has highlighted a report today on the shockingly deadly impact of Chinese air pollution as the company pushes forward with its non-invasive cardiovascular and respiratory device.
The company which specialising in cardiac, vascular and pulmonary monitoring devices noted that 1.6 million each year in China were related to pollution induced cardiac, vascular and pulmonary disease and that 55% of all deaths were caused by cardiorespiratory disease.
Data from the University of California study was based on Chinese air monitoring figures and is interpreted as confirming Uscom’s growth strategy in a number of key products.
These products include the Uscom blood pressure device and the Thor products, which are envisioned as being adopted as standard home care monitors of asthma and COPD. Discussions are ongoing for distribution of the Thor devices in the Chinese and U.S. markets.
The new suite of Thor digital spirometry devices is expected to slipstream Uscom’s flagship USCOM 1A and Uscom blood pressure products and expand Uscom technology into practice-leading positions in cardiac, vascular and pulmonary applications.
Uscom’s Thor Laboratories business is expected to increase the company’s revenue by A$500,000 and support its forecast FY2016 revenue estimate of circa $3.5 million+.
Uscom had revenue of $2.04 million in FY2015, up from $1.38 million in FY2014, $1.0 million in FY2013 and cash of $2.5 million.
Uscom’s acquisition of Thor last month gives the company access to accredited manufacturing close to its growing markets in Europe and the U.S.
Add to My Watchlist
What is My Watchlist?
